EGFR and cancer: Based on their efficacy in clinical trials, therapies that inhibit the EGFR signaling pathway, such as the small-molecule inhibitors, erlotinib (Tarceva®) and gefitinib (Iressa®), and the monoclonal antibodies, cetuximab (Erbitux®) and panitumumab (Vectibix®), are now routinely used in clinical practice to control these cancers [5–8].